Related Experiment Video
Updated: Jul 10, 2026
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Stress proteins in Alzheimer's disease
1New England OncoTherapeutics Inc., Cambridge, MA 02142, USA. rcsmith@newonc.com
Summary
Heat shock proteins help prevent toxic protein clumps in neurodegenerative diseases. Research suggests these proteins may offer neuroprotection in Alzheimer's disease, an area needing further exploration.
Area of Science:
- Molecular biology
- Neuroscience
- Protein biochemistry
Background:
- Protein misfolding and aggregation are implicated in neurodegenerative diseases.
- Molecular chaperones, including heat shock proteins (HSPs), play a role in protein homeostasis.
- HSPs are known to prevent protein misfolding and aggregate formation, aiding cellular survival.
Purpose of the Study:
- To review the existing literature on the role of heat shock proteins in Alzheimer's disease.
- To explore the potential neuroprotective functions of HSPs in the context of Alzheimer's disease pathology.
Main Methods:
- Literature review of scientific publications.
- Analysis of studies investigating heat shock proteins and neurodegenerative diseases.
- Focus on research related to Alzheimer's disease and proteinopathy.
Main Results:
- Heat shock proteins have demonstrated neuroprotective effects in animal models of Parkinson's and polyglutamine diseases.
- Evidence suggests HSPs may suppress neurotoxicity associated with abnormal protein accumulation.
- The role of HSPs in Alzheimer's disease neuroprotection is an emerging and underexplored area.
Conclusions:
- Heat shock proteins are critical for managing protein misfolding and aggregation.
- HSPs show therapeutic potential for neurodegenerative disorders characterized by protein toxicity.
- Further research is warranted to fully elucidate the neuroprotective capacity of heat shock proteins in Alzheimer's disease.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...